Galera Therapeutics Statistics
Total Valuation
Galera Therapeutics has a market cap or net worth of 2.58 million. The enterprise value is 145.18 million.
| Market Cap | 2.58M |
| Enterprise Value | 145.18M |
Important Dates
The next estimated earnings date is Friday, March 7, 2025.
| Earnings Date | Mar 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Galera Therapeutics has 54.39 million shares outstanding. The number of shares has increased by 43.53% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 54.39M |
| Shares Change (YoY) | +43.53% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 40.63% |
| Owned by Institutions (%) | 5.06% |
| Float | 32.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.40 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.36 |
Financial Position
The company has a current ratio of 9.74
| Current Ratio | 9.74 |
| Quick Ratio | 9.25 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -7.66 |
| Interest Coverage | -25.11 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -47.41% |
| Return on Capital (ROIC) | -66.94% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -2.80M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.29% in the last 52 weeks. The beta is 1.83, so Galera Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.83 |
| 52-Week Price Change | -74.29% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.10 |
| Relative Strength Index (RSI) | 58.68 |
| Average Volume (20 Days) | 432,937 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.03 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.71M |
| Pretax Income | -19.82M |
| Net Income | -19.61M |
| EBITDA | -17.47M |
| EBIT | -17.71M |
| Earnings Per Share (EPS) | -0.36 |
Balance Sheet
The company has 8.46 million in cash and 151.05 million in debt, giving a net cash position of -142.59 million or -2.62 per share.
| Cash & Cash Equivalents | 8.46M |
| Total Debt | 151.05M |
| Net Cash | -142.59M |
| Net Cash Per Share | -2.62 |
| Equity (Book Value) | -143.06M |
| Book Value Per Share | -2.63 |
| Working Capital | 7.99M |
Cash Flow
In the last 12 months, operating cash flow was -19.72 million and capital expenditures -9,000, giving a free cash flow of -19.73 million.
| Operating Cash Flow | -19.72M |
| Capital Expenditures | -9,000 |
| Free Cash Flow | -19.73M |
| FCF Per Share | -0.36 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Galera Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -43.53% |
| Shareholder Yield | -43.53% |
| Earnings Yield | -758.77% |
| FCF Yield | -763.65% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |